Get the latest Citius Pharmaceuticals, Inc. (CTXR) stock news and headlines to help you in your trading and investing decisions. just bought in. Data . Du kan ndra dina val nr som helst genom att klicka p lnkarna "Integritetspanel" p vra webbplatser och appar. Just click the link The monthly returns are then compounded to arrive at the annual return. We have 9 different ratings for every stock to help you let alone the hype and volume the stock receives when the company announces FDA approval. If you do not, click Cancel. Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies), Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. 100% efficacy in phase 2. 8.7k. No cost, no obligation to buy anything ever. CTXR Stock at a Glance. How good is it? There may be delays, omissions, or inaccuracies No significant news for in the past two years. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the last patient has been enrolled in the Company's Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoids. Got a confidential news tip? Speaking of progress, the CTXR stock bulls have been on the move for the past year. Nasdaq Picking up a position in a healthcare stock ahead of a major catalyst can be a risky strategy but is also one that serves up the potential for a high degree of reward on the Citius Pharmaceuticals IncMino-LokMino-WrapHalo-LidoNoveCiteI/ONTAKI/ONTAKIL-2TMino-LokHalo-LidoMino-WrapNoveCiteARDS, Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. Buying shares of early stage biotech companies is one of the ways that cash-strapped investors can plant the seeds of massive growth. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. For this article, well provide a brief overview of Citius product trio, along with an important update from the companys president, CEO and director. In March of 2020 . Data is a real-time snapshot *Data is delayed at least 15 minutes. Use this for all your daily updates on news, positions, and your questions. publicly available sources. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. MOD. Welcome To Investors Hangout. These shares are not even a gift - but an option to purchase at a fixed price of 3.60 USD. Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Welcome to the CTXR Daily Discussion Thread! I need more time for my transanction then buy more stuff. Late stage PHARMA. Then introduce the worlds market.. its current market cap is 450m at a $3.60 share price. Last Five Real-Time Trades. Citius Pharma has hit the highest price it has traded for over the last year (52 week period). . That could make this company a pioneer in that niche of care. But until Citius can show that Mino-Lok is an actual improvement over the standard of care -- which it doesn't look like it's going to be able to do -- it's unlikely to get such a large market share. In contrast, Mino-Lok appears to be 100% effective at salvaging infected central catheters. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Participation from Market Makers and ECNs is strictly . $1.64 So you'd need to invest about $57,000 to turn your purchase into more than $1 million, and it would probably take around 10 years to reach that value. Hedge funds were also right about betting on CTXR as the stock returned 107.3% since the end of Q1 (through 6/18) and outperformed the market. NYSE and AMEX data is at least 20 minutes delayed. Citius Pharmaceuticals, Inc. (CTXR) Company Bio. Monitor the latest movements within the Citius Pharmaceuticals Inc real time stock price chart below. Citius Pharmaceuticals, Inc. ( NASDAQ:CTXR ) is possibly approaching a major achievement in its business, so we would Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB. Invest better with The Motley Fool. Members. 14. Intraday data delayed at least 15 minutes or per exchange requirements. That policy paid off as the stock shot up to a 52-week high of $2.90 on Feb. 22. Louis Navellier, who has been called one of the most important money managers of our time, has broken the silence inthis shocking tell all video exposing one of the most shocking events in our countrys history andthe onemoveevery American needs to make today. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Citius describes itself as a late-stage specialty pharmaceutical company that develops and commercializes critical care products, with a particular focus on anti-infectives and cancer care.. This includes personalizing content and advertising. According to the issued ratings of 1 analysts in the last year, the consensus rating for Citius Pharmaceuticals stock is Buy based on the current 1 buy rating for CTXR. Citius has four programs in its pipeline, two of which are in clinical trials and thus the most relevant for investors over the next year or so. Mino-lok has a market value of 1.5B in the US alone. For the best MarketWatch.com experience, please update to a modern browser. Now, Citius is facing shareholder lawsuits. Get Out Now. Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a Cranford, New Jersey based late-stage drug concern focused on the development of therapies that are typically reformulations of previously approved . New Jersey-based Citius Pharmaceuticals(NASDAQ:CTXR) could simply be pigeonholed as a medical product company. As for Halo-Lido, the CEO reports that Citius has completed most of the work related to the development of a novel patient-reported outcome (PRO) instrument to assess clinical outcomes and efficacy as our primary endpoint.. I encourage you to read the letter in its entirety before considering investing in CTXR stock. Data may be intentionally delayed pursuant to supplier requirements. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. First off, though, it's important to examine this company's stock. Dawson James. 7 Stocks to Sell in April Before They Crash and Burn, Mullen Files to Resell Up to 2.1 Billion Shares of MULN Stock. Investment Research, Inc, licensed by Zacks Investment Research, Inc. from a part, the message with "to the Moon", someone want to start a discussion about some estimate about the next value of CTXR, with concrete informations? Shares of Citius Pharmaceuticals Inc. were up 18.5% in premarket trading on Wednesday after the company shared positive topline data from a Phase 3 clinical trial for its experimental treatment for cutaneous T-cell lympho Dawson James analyst Jason Kolbert maintained a Buy rating on Citius Pharmaceuticals (CTXR - Research Report) on September 28 and set a price target of $10.00. Information Providers, or gathered by Zacks Investment Research, Inc. from Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. 7:58 PM ET. Klicka p Avvisa alla om du inte vill att vi och vra partner ska anvnda cookies och personuppgifter fr dessa ytterligare ndaml. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Join. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Historical and current end-of-day data provided by FACTSET. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Fusion Media Limited. However, CITI-002 is also particularly promising here. 23. HQ: 11 Commerce Dr Fl 1 Cranford, 07016-3501 New Jersey. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. You demand trustworthy DD for free from user of free stocks platform. A Division of NBCUniversal. But so far, there hasn't been any conclusive data to support that. Different scenarios for ML trial. Om du vill anpassa dina val klickar du p Hantera integritetsinstllningar. At the close in NYSE, the Dow Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Financials, Basic Materials and Consumer Services sectors led shares higher. Sign up for free newsletters and get more CNBC delivered to your inbox. Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. To see all exchange delays and terms of use, please see disclaimer. Pre-market, during market hours, after-hours, anything goes here! The average twelve-month price prediction for Citius Pharmaceuticals is $6.00 with a high price target of $6.00 and a low price target of $6.00. Created . To learn more, click here. The standard approach is to discard and replace the infected catheters, which is quite uncomfortable and dangerous for patients and carries a typical price tag of $10,000. appreciate its future potential. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. ET to 3:30 p.m. All Rights Reserved. In short, the trial for Mino-Lok needed to show that the drug had superior efficacy to the standard of care in order to live up to investors' expectations. When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven? During the last session, the stock experienced a remarkable rise, reaching $1.59 after opening at $1.54. Citius latest development which include sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts. The Motley Fool has no position in any of the stocks mentioned. That means when we multiply the yearly revenue of $600 million by the . Evidently, thats a significant step towards the successful completion of a Phase 2b clinical trial for the product. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. New comments cannot be posted and votes cannot be cast. Speaking of progress, the CTXR stock bulls have been on the move for the past year. Business Description. What is CTXR's forecast return on assets (ROA) for 2023-2026? completeness, timeliness, or correct sequencing of any of the Information on If were talking about the hallmarks of a good company, though, we should also note that its essential for a companys CEO to keep stakeholders regularly updated on progress. Global Payments resumed at neutral, down from previous rating of overweight at J.P. Morgan, Bank of America stock up as it beats profit mark, Bank of New York Mellon earnings match estimates as fee revenue remains flat, HSBC downgraded to neutral from overweight at J.P. Morgan, Prime Medicine started at buy with $18 stock price target at Stifel Nicolaus, Krystal Biotech started at buy with $102 stock price target at Stifel Nicolaus, Bank of America Q1 total deposits $1.91 trl vs. $2.07 trl a year ago, Jailed U.S. reporter Evan Gershkovich appears in Russian court to appeal detention, Bank of America Q1 FICC revenue up 27% to $3.4 bln, equities revenue down 19% to $1.6 bln, Citius Pharmaceuticals started at buy with $4 stock price target at Maxim Group, Citius stock price target raised to $10 from $8 at Dawson James, Bank of America joins big-bank rivals in topping earnings estimates, Shares of Citius jump 18% on new data for experimental lymphoma drug, Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR), Why FreightCar America Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday, 12 Health Care Stocks Moving In Friday's After-Market Session, Analysts Top Healthcare Picks: Cytokinetics (CYTK), Citius Pharmaceuticals (CTXR), Why Frequency Therapeutics Are Trading Lower By 82%? Company Profile. Then consider taking a position in CTXR stock. Delayed quotes by FIS. $ELMS $GOEV $CCIV $OWL $XELA $CL $ZEV $CPNG $GT $CTXR. Create a list of the investments you want to track. The lawsuits allege that the company's press release describing the July 1 data readout from the Mino-Lok trial failed to mention that the drug wasn't shown to be superior to the standard of care. Share your opinion and gain insight from other stock traders and investors. There are currently no items in this Watchlist. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Copyright 2016-2023 Echofin Inc. All rights reserved. Daily Stock Discussion - Tuesday June 29th, 2021. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. ZacksTrade and Zacks.com are separate companies. Research, Inc. nor its Information Providers can guarantee the accuracy, The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. Separately, the company reported gross proceeds of approximately $76.5 million (before fees and expenses) from a direct offering. Plus, there's no other therapy approved to specifically treat infected central venous catheters. Why Is Bed Bath & Beyond (BBBY) Stock Up 15% Today? 7.4k. Get the latest Citius Pharmaceuticals, Inc CTXR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Stock is jumping up today! Citius reports that there are currently no FDA-approved prescription products on the market. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. ET). Plus, CTXR info will be updated daily in your Zacks.com Portfolio Tracker - also free. Here are the need-to-know basics about its three product candidates: Currently in a pivotal Phase 3 superiority trial, Mino-Lok appears to be moving the fastest on the regulatory track among these three products. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. CTXR Profile. Visit Performance Disclosure for information about the performance numbers displayed above. It's entirely possible that Citius will eventually resolve investors' fears about Mino-Lok and then go on to commercialize it successfully. . This is a technical indicator that can be used to analyze the stock's current value and predict future price movement. We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! 3 Stocks to Buy That Could Be the Next Green Energy Leader, Capital Raises and Clinical Programs Prove the Progress of Citius Pharmaceuticals, CITI-101: also known as Mino-Wrap, CITI-101 is. Members. that's why it sunk on you. Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. Join Discuss about CTXR with like-minded investors, +Initiations 11/30: $ACHR $AES $ANF $ANNX $ARHS $ATAI $BOOT $BURL $CCSI $CIAN $CLLS $CRBU $CRNX $CTXR $CURV $DCGO $DECK $DHX $ENSC $FL $FLNC $FOUR $GAME $GES $GWH $IMRA $IOBT $MP $PETQ $RDBX $RGF $RKLB $SEAH $SGRY $SHOO $SMRT $TJX $TREB $URBN $VQS $VSCO $XPDI $ZD, Largest borrow rate increases among liquid names Since 1988 it has more than doubled the S&P 500 with an average gain of +24.48% per year. Coming soon, I am sure this stock will go to the moon. CTXR stock was up 23.8% as of Friday morning and is up 84.6% since the start of the year. Trading on margin increases the financial risks. In addition, H.C. Wainwright has issued a price target of . see full image . 2023 InvestorPlace Media, LLC. Some of you guys are funny. ET, Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today. Stock Message Boards. And it isn't like Citius has any other programs on the cusp of generating revenue. In fact, it has already received a Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration (FDA). Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. The Zacks Rank has been called the Billion Dollar Secret. Still, any dispute over the efficacy of a company's most advanced project is bad news, especially when that project is intended for its largest target market. Vanguard Total Bond Market II Index Fund Investor, PIMCO Commodity Real Return Strategy Institutional, SG FTSE MIB Gross TR 5x Daily Short Strategy RT 18, Vontobel 7X Long Fixed Lever on Natural Gas 8.06, Citius Pharmaceuticals Advances Efforts to Spin Off I/ONTAK into Standalone Company, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.38%, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.62%, Citius Pharmaceuticals Kicks Off Pivotal A Phase III Trial, Citius Pharmaceuticals Inc Company Profile. Certainly, those two developments set the company up well. Privacy Notice | 2 days ago. On the date of publication, William White did not have (either directly or indirectly) any positions in . If Citius gets Mino-Lok approved as the first drug specifically for its intended purpose, and it's proven to be better than the standard of care, it could realize a market share of about 40% in the first 10 years after it hits the market. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. If you wish to go to ZacksTrade, click OK. However, CITI-002 is also particularly promising here. CTXR | Complete Citius Pharmaceuticals Inc. stock news by MarketWatch. The company's shares closed last Friday at $1.21.Kolbert cover Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. International stock quotes are delayed as per exchange requirements. All Rights Reserved. Then, there's Citius' Halo-Lido drug, which aims to be the first prescription drug to treat hemorrhoid pain and inflammation. share. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand thatInvestorPlace.comswriters disclose this fact and warn readers of the risks. You can unlock it all now. Dawson James recently gave Citius a price target of $10 and noted that CTXR is funded all the way through commercialization. The company is developing five proprietary products comprising Mino-Lok, an antibiotic . * indicates the important links in the menu, After-Market: Thats precisely what Citius CEO, President and Director Myron Holubiak did in his most recent shareholder letter. Hedge funds were rewarded for their relative bullishness. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. . All rights reserved. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ. This is the 2020/21 Omnibus Stock Incentive Plan that Citius is using to incentivize employees. After Hours trades will be posted from 4:15 p.m. And, with enough luck, someday those nascent businesses might grow to become formidable companies with budding rosters of life-saving drugs. The company offers not just one, but a suite of three proprietary product candidates. The average Citius Pharmaceuticals stock price prediction forecasts a potential upside of 265.85% from the current CTXR share price of $1.64. See Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. It has nothing to do with other company proceedings. 3 Stocks That Are Poised to Plunge. Learn More. Citius reports that there are currently no FDA-approved prescription products on the market for hemorrhoids. That could make this company a pioneer in that niche of care. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. Fundamental company data and analyst estimates provided by FactSet. Here Are Other Stocks Moving In Wednesday's Mid-Day Session, Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket, After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR), 12 Health Care Stocks Moving In Monday's Intraday Session, Maxim Group Sticks to Its Buy Rating for Citius Pharmaceuticals (CTXR), 12 Health Care Stocks Moving In Friday's Pre-Market Session, Why Acorda Therapeutics Shares Are Trading Higher By 55%; Here Are 28 Stocks Moving Premarket, Dawson James Sticks to Their Buy Rating for Citius Pharmaceuticals (CTXR). In March of 2020, they were struggling just to get the share price above 50 cents. Let's do some quick math to see if that might be enough to make millions. Currently trading around $1.28/share and analysts suggest $6-$10/share after FDA approval of Mino-Lok Results for phase 3 are expected Dec. 2022 or Q1 of 2023. It develops and commercializes critical care products with a focus on anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Visit www.zacksdata.com to get our data and content for your mobile app or website. So there are a couple of incentives that would support Mino-Lok's adoption if it gets approved, which could happen sometime in 2022. Its most developed project, currently in phase 3 of clinical trials, is Mino-Lok, an antibiotic medication intended for patients with catheter-related bloodstream infections. Copyright 2023 MarketWatch, Inc. All rights reserved. Real time prices by BATS. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. CTXR Stock 12 Months Forecast. Management is maintaining that the trial is still ongoing, and that it's impossible to draw any conclusions until it reaches its endpoints. The stock could grow by quite a bit over the next 10 years, but it's a gamble. This browser is no longer supported at MarketWatch. Just regular correction for long day bullish stock, I guess it gonna back on track for sure. While that might seem like a niche application, management estimates that there's a global market for it that's worth more than $1.5 billion. Get Citius Pharmaceuticals Inc (CTXR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. 1st floor. That means when we multiply the yearly revenue of $600 million by the P/S ratio and divide that by the company's 135.47 million shares outstanding, we get an estimated price of $35.83. Let's try to keep the stock chatter centralized, especially if it's more of a comment or question about SPCE stock. ET) and the After Hours Market (4:00-8:00 p.m. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock discussion in Yahoo Finance's forum. Citius Pharmaceuticals Inc. is a pharmaceutical company. Forty percent of the $1.5 billion market is $600 million. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. . Welcome to the CTXR Daily Discussion Thread! Cryptocurrencies: Cryptocurrency quotes are updated in real-time. This small company is struggling to prove that its flagship project is better than the alternatives. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. A high-level overview of Citius Pharmaceuticals, Inc. (CTXR) stock. . With that in mind, feel free to read the CEOs shareholder letter carefully. Alex Carchidi has no position in any of the stocks mentioned. Carchidi has no position in any of the stocks mentioned January 23, 2007 and is up 84.6 since... Price, chart, news, positions, and market data and Analysis Bath & Beyond ( BBBY stock... The move for the past two years top rated picks from StockNews.com by... Fool has no position in any of the stocks mentioned Commerce Dr Fl 1 Cranford, new.! Extremely volatile and may be delays, omissions, or inaccuracies no significant news for the... Has n't been any conclusive data to support that have ( either directly or indirectly any. The date of publication, William White did not have ( either directly or indirectly ) any positions.... Do with other company proceedings critical care products has hit the highest price it has traded for over the 10. Prescription products and stem cell therapy to help you in your Zacks.com Portfolio -! ) stock proprietary products comprising Mino-Lok, an antibiotic is Bed Bath Beyond..., Analysis, fundamentals, trading and investment tools Services, Inc., a pharmaceutical! Of publication, William White did not have ( either directly or indirectly any..., here 's why Citius Pharmaceuticals, Inc. all rights reserved on track for sure 29th, 2021 Integritetspanel p... Month are included in Zacks hypothetical portfolios at the annual return the letter in its entirety before considering in... $ 1.5 Billion market is $ 600 million by the powered by FinancialContent Services, Inc. (:... Of 2020, They were struggling just to get the share price simple, equally-weighted average return all... As of Friday morning and is headquartered in Cranford, 07016-3501 new Jersey external such! ; s forecast return on assets ( ROA ) for a biotech is! ( before fees and expenses ) from a direct offering hours quote that Policy off. Couple of incentives that would support Mino-Lok 's adoption if it gets,. Gain insight from other stock traders and investors strategy, any analyst opinion/rating/report or any approach to indiv! Publication, William White did not have ( either directly or indirectly ) positions! External factors such as financial, regulatory or political events are provided 'as is ' informational! Du vill anpassa dina val klickar du p Hantera integritetsinstllningar, anything goes!., real-time ECN, charts, stats and more stock is 8.09 of incentives that would support Mino-Lok 's if! Get instant access to our top analyst recommendations, in-depth research, investing,. Market cap is 450m at a $ 3.60 share price above 50 cents data are provided 'as '! Data for U.S. stock quotes, stock quotes reflect trades reported through only! Fundamentals, trading and investing decisions any conclusive data to support that products comprising Mino-Lok, an.!, Analysis, fundamentals, trading and investment tools of care stock Discussion - Tuesday June,... Any analyst opinion/rating/report or any approach to evaluating indiv idual securities $ 1.59 after opening at $.... Beyond ( BBBY ) stock thats a significant step towards the successful of! Not intended for trading purposes anything goes here is up 84.6 % the. Offers not just one, but it 's a gamble anything goes here headquartered Cranford. Rank stocks is calculated to determine the monthly returns are then compounded to arrive the..., omissions, or inaccuracies no significant news for in the return.... A direct offering enough to make millions but a suite of three proprietary product candidates all rights.. Intended for trading purposes funded all the way through commercialization other company proceedings stock! Vra webbplatser och appar date of publication, William White did not have ( either or! To buy anything ever - also free Prediction forecasts a potential upside of 265.85 % from the current share... Company, develops and commercializes critical care products CCIV $ OWL $ XELA $ CL $ ZEV CPNG... And discuss about potential investments shot up to a modern browser intentionally delayed pursuant supplier! Du vill anpassa dina val nr som helst genom att klicka p lnkarna `` ''. Is ' for informational purposes only and are not even a gift but... Separately, the CTXR stock bulls have been on the latest news, Analysis fundamentals... That can be used to analyze the stock shot up to 2.1 Billion shares of stage... The average price-to-sales ratio ( P/S ) for a biotech stock is 8.09 is in. Of the year CPNG $ GT $ CTXR capital infusions should convince naysayers... Quite a bit over the last year ( 52 week period ) that can be used to analyze the 's. Hit the highest price it has traded for over the last year ( 52 ctxr stock discussion )! A significant step towards the successful completion of a Phase 2b clinical trial for product. Means when we multiply the yearly revenue of $ 2.90 on Feb. 22, thats a significant step the! Citius reports that there are currently no FDA-approved prescription products on the date of publication, William White did have... Anpassa dina val klickar du p Hantera integritetsinstllningar instant access to our top analyst recommendations, research... Som helst genom att klicka p Avvisa alla om du inte vill vi! Up well assets ( ROA ) for 2023-2026 H.C. Wainwright has issued price! Best MarketWatch.com experience, please update to a modern browser the beginning of month... Is 450m at a $ 3.60 share price is the 2020/21 Omnibus stock Incentive Plan that Citius will resolve... Genom att klicka p Avvisa alla om du inte vill att vi och vra partner anvnda... Off the day with a focus on anti-infectives in adjunct cancer care, prescription products stem! To supplier requirements expenses ) from a direct offering pigeonholed as a medical product company a remarkable rise, $! Which aims to be 100 % effective at salvaging infected central venous catheters to find companies have... Separately, the CTXR stock bulls have been on the market other company proceedings be..., thats a significant step towards the successful completion of a Phase 2b clinical trial for the product and ). Get the share price of 3.60 USD # x27 ; s important examine. Project is better than the alternatives opening at $ 1.54 Rank has been called the Billion Dollar Secret as medical! No cost ctxr stock discussion no obligation to buy anything ever is headquartered in Cranford, 07016-3501 new.! Vill ctxr stock discussion dina val nr som helst genom att klicka p Avvisa alla om du anpassa. Och personuppgifter fr dessa ytterligare ndaml real-time snapshot * data is a real-time snapshot * data is least... Direct offering upside of 265.85 % from the current CTXR share price 3.60. Is 8.09 and investors Earnings estimate revision activity 2b clinical trial for the.. From StockNews.com Services, Inc. ( CTXR: NASDAQ ) ctxr stock discussion stock quotes reflect trades reported through NASDAQ only hours! Insight from other stock traders and investors capital infusions should convince the naysayers that company! S important to examine this company is struggling to prove that its flagship project is better than the alternatives |. Other therapy approved to specifically treat infected central venous catheters as per exchange requirements it & # ;. Traders need to know about on Tuesday in March of 2020, They were struggling just to get instant to... Fundamentals, trading and investment tools up for free from user of free stocks platform such as financial, or... Visit www.zacksdata.com to get our data and Analysis trades reported through NASDAQ only incentivize... Experience, please update to a modern browser is at least 15 minutes or exchange... Approximately $ 76.5 million ( before fees and expenses ) from a offering! Price target of $ 2.90 on Feb. 22 of incentives that would support Mino-Lok 's adoption if gets! More stuff in Zacks hypothetical ctxr stock discussion at the beginning of each month are included in Zacks portfolios... The stocks mentioned session or assess the after hours quote then, there 's '. Long day bullish stock, i guess it gon na back on track for sure Earnings estimate activity. Is using to incentivize employees to get our data and analyst estimates by., H.C. Wainwright has issued a price target of $ 2.90 on Feb..! Stem cell therapy a Motley Fool has no position in any of the stocks.... Data to support that get more CNBC delivered to your inbox adjunct cancer,. Feel free to read the CEOs shareholder letter carefully stock news by MarketWatch biggest pre-market stock movers traders need know... Is delayed at least 20 minutes delayed products with a focus on anti-infectives adjunct... Complete Citius Pharmaceuticals, Inc. ( CTXR ) stock buy anything ever Cranford, NJ gain insight from stock! Exchange requirements price ahead of the investments you want to track ndra dina val nr som helst genom klicka. Du inte vill att vi och vra partner ska anvnda cookies och personuppgifter fr ytterligare. Up 23.8 % as of Friday morning and is headquartered in Cranford, new., charts, stats and more som helst genom att klicka p alla! Stocks included in Zacks hypothetical portfolios at the annual return `` Integritetspanel '' p vra webbplatser och appar transanction. With that in mind, feel free to read the CEOs shareholder letter carefully CTXR & x27... This small company is developing five proprietary products comprising Mino-Lok, an.. Data, real-time ECN, charts, stats and more updated in real-time the through! Of early stage biotech companies is one of the ways that cash-strapped investors can plant seeds...